Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
Braybrooke JP, Propper DJ, O'Byrne KJ, Koukourakis MI, Patterson AV, Houlbrook S, Love SD, Varcoe S, Taylor M, Ganesan TS, Talbot DC, Harris AL. Braybrooke JP, et al. Among authors: taylor m. Br J Cancer. 2000 Jul;83(2):219-24. doi: 10.1054/bjoc.2000.1230. Br J Cancer. 2000. PMID: 10901374 Free PMC article. Clinical Trial.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. Generali D, et al. Among authors: taylor m. Br J Cancer. 2014 Jul 8;111(1):46-54. doi: 10.1038/bjc.2014.236. Epub 2014 May 29. Br J Cancer. 2014. PMID: 24874483 Free PMC article. Clinical Trial.
10,077 results
You have reached the last available page of results. Please see the User Guide for more information.